Pfizer's Upjohn has merged with Mylan to form Viatris

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Pfizer's Upjohn has merged with Mylan to form Viatris sits in the top decile of US sponsors by registered trial count (#186 of 15,742 sponsors by registered trial count).

158 total trials none currently recruiting 138 completed later-stage tilt top decile by trial count

Pfizer's Upjohn has merged with Mylan to form Viatris: 158 sponsored US clinical trials, none currently recruiting.

Pfizer's Upjohn has merged with Mylan to form Viatris sponsors 158 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 138 completed. 128 of these trials are in Phase 3-4 (later-stage) and 24 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 3 trials.

Top-decile sponsor footprint

Pfizer's Upjohn has merged with Mylan to form Viatris ranks in the top decile of sponsors by registered trial count (#186 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 58/100

138 of 158 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

158 total, page 1 of 4

TERMINATED Phase 3

Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder

NCT03768726

COMPLETED Phase 1

Bioavailability Study of Pregabalin Extended Release Formulation With Various Release Rates in Healthy Volunteers

NCT02725112

COMPLETED Phase 1

A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects

NCT02637193

TERMINATED Phase 4

Effects of Oral Sildenafil on Mortality in Adults With PAH

NCT02060487

COMPLETED Phase 3

A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.

NCT02072824

TERMINATED Phase 3

Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder

NCT02075047

COMPLETED Phase 3

Actual Use Trial of Atorvastatin Calcium 10 mg

NCT01964326

COMPLETED Phase 3

A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn

NCT01720524

COMPLETED Phase 3

Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers

NCT01888497

COMPLETED Phase 3

A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.

NCT01747915

COMPLETED Phase 3

Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain

NCT01701362

COMPLETED

Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)

NCT01302080

COMPLETED Phase 3

A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

NCT01463306

COMPLETED Phase 3

Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain

NCT01455415

COMPLETED Phase 3

A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression

NCT01432236

COMPLETED Phase 3

Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)

NCT01474772

COMPLETED Phase 3

A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years

NCT01389596

COMPLETED Phase 1

Investigation Of Absorption And Pharmacokinetics Of A Single Dose Of Controlled Release Pregabalin Tablet Administered Fasted In The Evening or Immediately Following A 600-750 Calorie Evening Meal As Compared To Single Dose Of Immediate Release Pregabalin Capsule In Healthy Volunteers

NCT01321671

COMPLETED Phase 1

An Investigation Of The Absorption And Pharmacokinetics Of A Single Dose Of A Controlled Release (CR) Pregabalin Tablet Following A Low, Medium, And High-Fat Evening Meal As Compared To A Single Dose Of The Immediate Release (IR) Pregabalin Capsule In Healthy Volunteers

NCT01257529

COMPLETED Phase 1

An Investigation Of The Absorption And Pharmacokinetics Of A Single Dose Of A Controlled Release (CR) Pregabalin Tablet Following Various Sized Lunches As Compared To A Single Dose Of The Immediate Release (IR) Pregabalin Capsule In Healthy Volunteers

NCT01270815

COMPLETED Phase 3

Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia

NCT01270828

COMPLETED Phase 3

Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients

NCT01271933

TERMINATED Phase 4

Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder

NCT01302938

COMPLETED Phase 3

Once-A-Day Pregabalin For Partial Seizures

NCT01262677

COMPLETED Phase 1

Investigation Of Absorption And Pharmacokinetics Of A Single Dose Of Controlled Release Pregabalin Tablet Administered Fasted At Bedtime Or Immediately Following A 400-500 or 600-750 Calorie Evening Meal As Compared To Single Dose Of Immediate Release Pregabalin Capsule In Healthy Volunteers

NCT01291524

COMPLETED Phase 1

Pharmacokinetics Of Alprazolam Sublingual Tablet Versus Conventional Tablet

NCT01256151

TERMINATED

Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study

NCT01280747

COMPLETED Phase 4

Pregabalin In Adolescent Patients With Fibromyalgia

NCT01020526

TERMINATED Phase 3

Pregabalin Trial In HIV Neuropathic Pain

NCT01145417

COMPLETED Phase 4

Adolescent Fibromyalgia Study

NCT01020474

COMPLETED Phase 1

A Study To Assess The Pharmacokinetics, Safety, And Tolerability Of A Pregabalin Controlled Release Formulation Administered Following Various Sized Caloric Meals As Compared To The Pregabalin Immediate Release Formulation

NCT01080612

TERMINATED Phase 3

Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy

NCT01049217

COMPLETED Phase 3

Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy

NCT01057693

COMPLETED

Effectiveness Of A Program That Includes Counseling And Patient Support On Adherence To Treatment With Lipitor

NCT01078285

COMPLETED Phase 3

Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance

NCT00991276

COMPLETED Phase 1

Effects Of Eplerenone On Serum Aldesterone And Plasma Renin Activity

NCT00990223

COMPLETED Phase 4

A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects

NCT00807846

COMPLETED Phase 1

Bioavailability of 3 Sildenafil Oral Disintegrating Tablet Formulations Compared to the Standard Oral Tablet

NCT00950404

COMPLETED Phase 1

Pharmacokinetics Of Celecoxib Test Formulations

NCT00925106

COMPLETED Phase 3

Effects Of Pregabalin (Lyrica) On Sleep Maintenance In Subjects With Fibromyalgia

NCT00883740

TERMINATED

Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis

NCT00688545

COMPLETED Phase 3

Atorvastatin Three Year Pediatric Study

NCT00827606

COMPLETED Phase 1

Ziprasidone Pharmacokinetics Using a Reduced Food Effect Formulation Compared to Pharmacokinetics From Commercial Capsules

NCT00821444

COMPLETED Phase 1

An fMRI Study Of Brain Response In Patients With Fibromyalgia

NCT00760474

COMPLETED Phase 3

Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients

NCT00806026

COMPLETED

A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION

NCT00759174

COMPLETED Phase 1

Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects.

NCT00795938

COMPLETED Phase 1

Bioequivalence Study Of Pediatric Appropriate Formulation

NCT00758004

COMPLETED Phase 1

A Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects

NCT00866463

COMPLETED Phase 4

Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet

NCT00917579

Page 1 of 4 Next →

How the Pfizer's Upjohn has merged with Mylan to form Viatris archive is shaped

158 indexed studies, none listed as recruiting (0% open); 138 completed (87%).

Phase mix: 128 late (III/IV) vs 24 early (I/II) (later-stage heavy).

Top condition: Healthy (3 trials), 9 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Pfizer's Upjohn has merged with Mylan to form Viatris: archived-pipeline peers nationwide

Peers matched on 158 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Pfizer's Upjohn has merged with Mylan to form Viatris sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 050100150200 0%5%10%15%20%25% Total trials Recruiting share Pfizer's Upjohn has merged with Mylan to form ViatrisGalderma R&DAnn & Robert H Lurie Children's Hospital of ChicagoUniversity of South CarolinaAlexion Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Pfizer's Upjohn has merged with Mylan to form Viatris sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Pfizer's Upjohn has merged with Mylan to form Viatris sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 158 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Pfizer's Upjohn has merged with Mylan to form Viatris page

158 registered trials is a research-attention snapshot, not an endorsement of Pfizer's Upjohn has merged with Mylan to form Viatris or any single study.

  • None of Pfizer's Upjohn has merged with Mylan to form Viatris's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Healthy is the condition Pfizer's Upjohn has merged with Mylan to form Viatris studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Pfizer's Upjohn has merged with Mylan to form Viatris pipeline card: 158 registered trials from official public datasets.Report a data error.